Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GMI-1271 in Healthy Adults
NCT02168595Phase 1Completed
- Sponsor
- GlycoMimetics
- Start
- Jun 2014
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of uproleselan in acute myeloid leukemia (AML) (3 cohorts), sponsored by GlycoMimetics. Primary endpoint: Treatment related adverse events. Started Jun 2014; status: completed.
02
Drugs
uproleselan
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02168595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02168595.